Deadline: 28-Oct-2025
The Pfizer, in collaboration with the Hemostasis & Thrombosis Research Society (HTRS), has announced a new Independent Medical Education grant opportunity designed to support institutions with limited access to hemophilia-focused educational resources.
This initiative offers a unique chance for selected organizations to host a Visiting Professorship aimed at addressing specific knowledge gaps in hemophilia care, particularly around shared decision-making (SDM) and emerging therapeutic options.
Through this program, clinicians, physician-scientists, and multidisciplinary care teams at recipient institutions will have the opportunity to coordinate a tailored educational experience led by a distinguished Visiting Professor. Each professor will be selected by HTRS based on the institution’s identified educational needs, ensuring that the program content directly targets areas where support and advancement are most needed.
Eligible applicants include accredited academic institutions such as medical, nursing, dental, pharmacy, and allied health schools, as well as nonprofit professional organizations and medical societies. Only organizations are eligible to apply—individual practitioners or unaffiliated physician groups are not permitted. Each application must name a project or program lead who is either an employee or contractor of the applying organization, and who will be responsible for coordinating the program locally.
The grant will provide up to $7,500 USD per recipient site to cover local logistical costs, including venue rental, audiovisual needs, staffing, and onsite management. Importantly, the travel expenses and honorarium for the Visiting Professor will be handled separately by HTRS and should not be included in the grant budget. Approximately eight organizations will be selected to participate in this educational initiative.
Interested institutions must complete an online application outlining the specific medical knowledge gaps and challenges they face in hemophilia care. The application should also include a proposed agenda for a program of up to two days in length, clearly defined educational objectives, and anticipated six-month outcomes. These outcomes should demonstrate enduring improvements in patient care and physician knowledge resulting from the program.
By connecting institutions with leading experts in hemophilia and fostering focused education on SDM and new treatment approaches, this program aims to elevate the standard of care in underserved settings. It is a strategic investment in both clinician development and patient outcomes, providing access to specialized expertise where it is needed most.
For more information, visit Pfizer.